… current status of drug development for PD. We focus on the drugs that have entered clinical
phases, mainly phases II and III, but we include a brief overview of the drugs in phase I trials. …

… In addition, computer-assisted drug design methods are a promising approach to developing
… review, we present current approaches for developing new drugs for Parkinson’s disease. …

… Parkinson's disease (PD) are aimed at addressing motor symptoms but there is no therapy
focused on modifying the course of the disease… drug delivery systems for Parkinson's disease. …

… for Parkinson's disease (PD) are mainly dopaminergic drugs. However, dopaminergic drugs
… Recent studies into drug development focused on emerging new molecular mechanisms, …

… For many years, levodopa has given most patients with Parkinson's disease excellent
symptomatic … drugs in development that target the primary motor disorder in Parkinson's disease. …

… We examined the ICTRP to determine the characteristics of Parkinson’s disease trials …
history of drug development in Parkinson’s disease, characterize trends in drug development, and …

… In this latter regard, there has been much interest in drug repurposing (the use of
established drugs for a new indication), with many drugs being reported to affect PD-relevant …

… and characterization of these cells is required before their full potential for drug development
… of Parkinson’s disease can only lead to better decisions and translation at all levels of drug …

… A major challenge in Parkinson disease (PD) will be to turn an emerging and expanding
pipeline of novel disease-modifying candidate compounds into therapeutics. Novel targets …

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that primarily affects
elderly people and constitutes a major source of disability worldwide. Notably, the …